Large Inflow of Money Detected in Shire plc

Shire plc (SHPG) : Mondays money flow data in Shire plc (SHPG) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $25.43 million, whereas, $24.41 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.04, in favor of the bulls. The total money flow into the stock was $1.02 million clearly indicating that the smart money has been buying into the stock on weakness.

In comparison, the money flow in block deals was $0 million. The total value of block trades done on upticks was $0 million. Shire plc (SHPG) fell $0.18 and traded at $198.75, down -0.09% for the day, over previous days close. On a weekly basis, the shares are -1.06% over the previous weeks close.


Shares of Shire plc rose by 0.8% in the last five trading days and 3.92% for the last 4 weeks. Shire plc is up 12.32% in the last 3-month period. Year-to-Date the stock performance stands at -2.57%.

Shire plc (NASDAQ:SHPG): The stock opened at $199.24 on Monday but the bulls could not build on the opening and the stock topped out at $200.18 for the day. The stock traded down to $198.43 during the day, due to lack of any buying support eventually closed down at $198.89 with a loss of -0.02% for the day. The stock had closed at $198.93 on the previous day. The total traded volume was 758,695 shares.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.